Merck & Co. (MRK) shares clocked seven straight sessions of gains, as the stock was up 0.2% at $124.1 on Tuesday. The global ...

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a ...

Shares of Merck & Co. Inc. MRK rallied 1.28% to $123.82 Monday, on what proved to be an all-around poor trading session for ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, ...

Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...

Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios. Merck stands ...

Merck started 2026 on a high note. Read why MRK stock is still one of the best choices among Big Pharma players for long-term-oriented investors.